Reducing Adverse Events Through Dose Optimization
Tanios S. Bekaii-Saab, MD, discusses minimizing the toxicities associates with tyrosine kinase inhibitors (TKIs) through dose optimizations strategies, which are of particular interest at TKIs are combined with immune checkpoint inhibitors that also may impact the liver.
Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
Dr. Tanios Bekaii-Saab discusses the results of a systematic review/meta-analysis intended to assess the impact of EGFR-targeted therapies on clinical outcomes in patients with HER2-positive metastatic colorectal cancer.
The Evolving Treatment Landscape of HCC
Closing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.
Later-Line IO Therapy for Advanced Hepatocellular Carcinoma
Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.
Selecting Therapy for Advanced HCC Following Atezo-Bev Failure
Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
Selecting Therapy for Advanced HCC Following TKI Failure
Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.
Patient Profile 3: Second-Line Therapy for Advanced HCC
Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.
Frontline Therapy for Advanced HCC: Novel Combination Strategies
Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.
Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC
Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.
Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC
Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.
Role of Hepatitis Status in Selecting Therapy for HCC
Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.
Real-World Selection of Frontline Combination Therapy for Advanced HCC
Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.
HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC
Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.
Management of HCC: Advances in Biomarkers and Screening
A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.
Selection and Use of Systemic Therapy in Intermediate Stage HCC
Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.
Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC
Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC
Early-Stage HCC: What is the Role of Neoadjuvant Therapy?
Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.
Early-Stage HCC: Role of Adjuvant Therapy
A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.
Patient Profile 1: Resection for Early/Intermediate Stage HCC
Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.
Gastrointestinal Cancers Recap at ASCO 2022: Dr Tanios Bekaii-Saab
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Dr. Bekaii-Saab on the Uptake of Precision Medicine in CRC
Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.
Dr. Bekaii-Saab on Improved Sequencing Strategies in HCC
Tanios S. Bekaii-Saab, MD, FACP, discusses improved sequencing strategies in hepatocellular carcinoma.
Dr. Bekaii-Saab on the Future of Telemedicine in CRC
Tanios S. Bekaii-Saab, MD, FACP, discusses the future of telemedicine in colorectal cancer.
Dr. Bekaii-Saab on the Emergence of Targeted Therapy in CRC
Tanios S. Bekaii-Saab, MD, FACP, discusses the emergence of targeted therapy in colorectal cancer.
Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the tolerability of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.
Dr. Bekaii-Saab on the Impact of the BEACON CRC Study in BRAF-Mutated CRC
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of the BEACON CRC trial in patients with BRAF V600E-mutated metastatic colorectal cancer.
Molecular Advances in Colorectal Cancer Are "Only the Tip of the Iceberg"
There has been a significant evolution in the care of patients with metastatic colorectal cancer over the past 20 years. However, this is only the tip of the iceberg and we are going to see more and more subgroups being defined and refined with many more rationally targeted agents matching these alterations.
Dr. Bekaii-Saab on Resistance to Targeted Therapy in CRC
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses resistance to targeted therapy in the treatment of patients with colorectal cancer.
Dr. Bekaii-Saab on Challenges With Precision Medicine in CRC
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the challenges of bringing a precision medicine approach into the clinic in colorectal cancer.
Dr. Bekaii-Saab on the Impact of Next-Generation Sequencing in mCRC
Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512